真实世界中左心室辅助装置临床结局与医疗支出:CLEAR-LVAD研究
HeartMate 3较HeartMate II和其他VAD的1年死亡风险更低,住院更少,且Medicare支出更低。
要点
- HeartMate 3较HeartMate II的1年死亡校正HR为0.64(95%CI 0.52-0.79,p<0.001)。
- HeartMate 3较其他VAD的1年死亡校正HR为0.51(95%CI 0.42-0.63,p<0.001)。
- HeartMate 3较其他VAD每患者年住院更少,平均住院日更短,Medicare支出更低。
核心结论
- 在真实世界Medicare行政数据集中,HeartMate 3较其他当代商用LVAD具有更优生存、更少医疗资源使用和更低医疗支出。
研究设计与样本
- 共识别4195例de-novo LVAD植入的Medicare按服务收费受益人(HeartMate 3 821例;HeartMate II 1840例;其他VAD 1534例)。
- 生存结局采用按LVAD类型分层的Cox比例风险模型比较,并用倾向性评分匹配验证;医疗资源利用采用非参数bootstrap分析。
主要发现
- HeartMate 3 vs HeartMate II的1年死亡校正HR为0.64(95%CI 0.52-0.79,p<0.001),倾向性评分匹配分析确认。
- HeartMate 3 vs 其他VAD的1年死亡校正HR为0.51(95%CI 0.42-0.63,p<0.001)。
- HeartMate 3 vs 其他VAD每患者年住院分别为2.8 vs 3.2次(p<0.01),平均住院日分别为25.2 vs 31.3天(p<0.01),平均少6.1天。
- 在存活条件下,HeartMate 3 vs HeartMate II的Medicare支出差异为-$10,722(p<0.001,降低17.4%),vs 其他VAD为-$17,947(p<0.001,降低26.1%)。
关键数值与推荐
- 主要结局为1年生存率和Part A Medicare总支付。
- HeartMate 3 vs HeartMate II的1年死亡校正HR 0.64(95%CI 0.52-0.79,p<0.001)。
- HeartMate 3 vs 其他VAD的1年死亡校正HR 0.51(95%CI 0.42-0.63,p<0.001)。
- HeartMate 3 vs 其他VAD每患者年住院2.8 vs 3.2次(p<0.01),平均住院日25.2 vs 31.3天(p<0.01)。
- HeartMate 3 vs HeartMate II的Medicare支出差异-$10,722(p<0.001,降低17.4%),vs 其他VAD -$17,947(p<0.001,降低26.1%)。
临床怎么用
- 在耐久性LVAD选择中,HeartMate 3与更优的1年生存、更少住院和更低Medicare支出相关,可作为真实世界决策参考。
- 评估LVAD经济负担时,除设备本身外,应纳入住院次数、住院日和Part A Medicare支付等资源利用指标。
局限性
- 为回顾性观察性研究,基于Medicare按服务收费受益人行政数据,可能存在选择偏倚和未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several distinctly engineered left ventricular assist devices (LVADs) are in clinical use. However, contemporaneous real world comparisons have not been conducted, and clinical trials were not powered to evaluate differential survival outcomes across devices. OBJECTIVES: Determine real world survival outcomes and healthcare expenditures for commercially available durable LVADs. METHODS: Using a retrospective observational cohort design, Medicare claims files were linked to manufacturer device registration data to identify de-novo, durable LVAD implants performed between January 2014 and December 2018, with follow-up through December 2019. Survival outcomes were compared using a Cox proportional hazards model stratified by LVAD type and validated using propensity score matching. Healthcare resource utilization was analyzed across device types by using nonparametric bootstrap analysis methodology. Primary outcome was survival at 1-year and total Part A Medicare payments. RESULTS: A total of 4,195 de-novo LVAD implants were identified in fee-for-service Medicare beneficiaries (821 HeartMate 3; 1,840 HeartMate II; and 1,534 Other-VADs). The adjusted hazard ratio for mortality at 1-year (confirmed in a propensity score matched analysis) for the HeartMate 3 vs HeartMate II was 0.64 (95% CI; 0.52-0.79, p< 0.001) and for the HeartMate 3 vs Other-VADs was 0.51 (95% CI; 0.42-0.63, p < 0.001). The HeartMate 3 cohort experienced fewer hospitalizations per patient-year vs Other-VADs (respectively, 2.8 vs 3.2 EPPY hospitalizations, p < 0.01) and 6.1 fewer hospital days on average (respectively, 25.2 vs 31.3 days, p < 0.01). The difference in Medicare expenditures, conditional on survival, for HeartMate 3 vs HeartMate II was -$10,722, p < 0.001 (17.4% reduction) and for HeartMate 3 vs Other-VADs was -$17,947, p < 0.001 (26.1% reduction). CONCLUSIONS: In this analysis of a large, real world, United States. administrative dataset of durable LVADs, we observed that the HeartMate 3 had superior survival, reduced healthcare resource use, and lower healthcare expenditure compared to other contemporary commercially available LVADs.
引用
- Pagani FD, Mehra MR, Cowger JA, et al. Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD study. J Heart Lung Transplant. 2021. PMID: 33744086. doi:10.1016/j.healun.2021.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。